Blitz Bureau
NEW DELHI: The Thiruvananthapuram-headquartered HLL has found a place alongside some of the world’s leading pharmaceutical and women’s healthcare companies in the rapidly expanding global hormonal contraceptive market.
HLL Lifecare Limited (HLL), a Mini Ratna Central Public Sector Enterprise under the Union Ministry of Health and Family Welfare, has been listed among the leading players in the global hormonal contraceptive market in a new industry report by international market research and consulting firm Spherical Insights & Consulting.
The recognition comes as HLL completes 60 years, offering a significant milestone for a company that began with a relatively focused mandate in contraceptive manufacturing and has since evolved into a diversified healthcare enterprise with operations spanning pharmaceuticals, diagnostics, hospital products, retail pharmacies, and healthcare infrastructure.
The Spherical Insights report, covering the 2026-35 period, places HLL alongside major global pharmaceutical and women’s healthcare companies.
It estimates that the global hormonal contraceptive market, valued at $20.84 billion in 2025, will expand to Rs 33.92 billion by 2035.
Growing awareness of reproductive health, wider adoption of family planning programmes, and increasing access to modern contraceptive methods are expected to drive the market’s expansion.
For HLL, the global recognition underlines the transformation of a Kerala-headquartered public sector undertaking into a company with an international footprint.
With seven manufacturing facilities across India, HLL supplies contraceptive and family planning products not only to the Central and state governments but also to United Nations agencies, international procurement organisations and public health programmes in several countries.
